Physician profile
John R Dailey
NPI 1255393146
$1,683.21
in general payments reported to CMS, 2019-2025
19 companies · $340 in 2025
The $340 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $132 · 2021: $374 · 2022: $284 · 2023: $196 · 2024: $191 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.01 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $290.51 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Abbvie INC. | $254.71 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $211.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $188.52 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $101.61 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.28 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $89.92 | 2022-2025 | Miebo, Infuse, Xiidra |
| Oyster Point Pharma, INC. | $87.58 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $61.62 | 2019-2021 | |
| Amgen INC. | $58.52 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $57.69 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $39.28 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $33.85 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.92 | 2022 | |
| Thea Pharma INC. | $20.87 | 2024 | Iyuzeh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $19.40 | 2022 | |
| Shire North American Group INC | $18.82 | 2019 | |
| Biotissue Holdings INC. | $15.18 | 2025 | |
| Eyevance Pharmaceuticals LLC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.